Use of berbamine dihydrochloride in preparation of Ebola virus inhibitor

US11654141B2 · kind B2 · utility

Assignee

• Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences · CN

Inventors

• Shan Cen · Beijing, CN
• Quanjie Li · Beijing, CN
• Dongrong Yi · Beijing, CN
• Yi Shi · Beijing, CN
• Han Wang · Beijing, CN
• Jinming Zhou · Beijing, CN

Key dates

• Filing date: Jun 19, 2019
• Grant date: May 23, 2023
• Expiry date: Dec 2, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 μM, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.